FDA Tinkers With Animal Feed Record Rules
Published Date: 6/18/2026
Notice
Summary
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
Analyzed Economic Effects
6 provisions identified: 2 benefits, 4 costs, 0 mixed.
Recordkeeping Burden: Registered Licensed Feed Mills
Registered licensed commercial feed mills (768 respondents) have estimated total annual responses of 2,241,792 and an average burden of 0.305 hours (18.3 minutes) per response, for a total of 683,747 hours annually under 21 CFR part 225 recordkeeping requirements.
Recordkeeping Burden: Type A Medicated Article Manufacturers
Manufacturers of Type A medicated articles (65 respondents) have an estimated 1,370 disclosures per respondent for a total of 89,050 annual disclosures and an average burden of about 1 hour per disclosure, totaling 89,050 hours annually under 21 CFR part 226.
Net Reduction in Estimated Recordkeeping Burden
FDA updated its inventory and reduced the number of medicated feed mill recordkeepers by 2,722, which corresponds to a reduction of 13,731,017 records and a decrease of 913,153 recordkeeping hours in its estimates.
Recordkeeping Burden: Non-licensed Commercial Feed Mills
Nonregistered, non-licensed commercial feed mills (1,658 recordkeepers) have an estimated 150,878 total annual records, an average burden of 1.44 hours per record, and a total of 217,265 recordkeeping hours annually under 21 CFR part 225.
Recordkeeping Burden: Non-licensed Mixer/Feeders
Nonregistered, non-licensed mixer/feeders (3,400 respondents) are estimated to have 309,400 total annual disclosures with an average burden of 1.36 hours per disclosure, totaling 420,784 hours annually for recordkeeping under 21 CFR part 225.
OMB Collections Consolidated into 0910-0152
The FDA is consolidating reporting for current good manufacturing practices (CGMPs) for Type A medicated articles and medicated feeds into one OMB control number (0910-0152) and will discontinue OMB control number 0910-0154. The agency requests public comments by July 20, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12239 — Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals
The FDA wants your thoughts on how they collect info about using drugs in animals in ways not originally approved (called extralabel use). This affects vets, farmers, and animal drug makers who report this info. You’ve got until August 17, 2026, to share your comments—no cost changes, just making sure the paperwork is clear and easy.
2026-12236 — SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12238 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
The FDA is asking for public feedback by July 20, 2026, on their rules that keep dietary supplements safe and made right. These rules affect companies that make, package, label, or store supplements, helping ensure products are high quality without adding extra costs. This review keeps the safety standards up-to-date and clear for everyone involved.
2026-12166 — Medical Devices; Radiology Devices; Classification of the Radiological Machine Learning-Based Quantitative Imaging Software With Predetermined Change Control Plan
The FDA is officially putting radiology software that uses machine learning and has a set plan for updates into a safer, easier-to-manage category called Class II. This change helps make sure the software is safe and effective while speeding up patient access to cool new tech. It’s been effective since early 2023, so companies can expect fewer hoops to jump through without extra costs or delays.
Previous / Next Documents
Previous: 2026-12236 — SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.
Next: 2026-12238 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
The FDA is asking for public feedback by July 20, 2026, on their rules that keep dietary supplements safe and made right. These rules affect companies that make, package, label, or store supplements, helping ensure products are high quality without adding extra costs. This review keeps the safety standards up-to-date and clear for everyone involved.